Royalty Pharma Plc Net Assets
Royalty Pharma Plc net assets. Based on the latest financial reports, Royalty Pharma Plc (RPRX) has net assets worth $9.94 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($19.82 Billion) and total liabilities ($9.88 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Royalty Pharma Plc (RPRX) net asset quality to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.94 Billion |
| % of Total Assets | 50.15% |
| Annual Growth Rate | 25.84% |
| 5-Year Change | -5.21% |
| 10-Year Change | 117.82% |
| Growth Volatility | 2064.72 |
Net Assets of Royalty Pharma Plc (2000–2025)
Net assets of Royalty Pharma Plc from 2000 to 2025. This chart illustrates how Royalty Pharma Plc's net assets have evolved over time, based on quarterly financial data. Also explore net asset growth rate of Royalty Pharma Plc to track the company's year-over-year net asset growth rate.
Annual Net Assets for Royalty Pharma Plc (2000–2025)
The table below shows the annual net assets of Royalty Pharma Plc from 2000 to 2025. For live market cap and overall valuation, see market cap of Royalty Pharma Plc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $9.71 Billion | -6.07% |
| 2024-12-31 | $10.34 Billion | +2.56% |
| 2023-12-31 | $10.08 Billion | +5.87% |
| 2022-12-31 | $9.53 Billion | -7.06% |
| 2021-12-31 | $10.25 Billion | -31.55% |
| 2020-12-31 | $14.97 Billion | +143.80% |
| 2019-12-31 | $6.14 Billion | +34.92% |
| 2018-12-31 | $4.55 Billion | +1.85% |
| 2017-12-31 | $4.47 Billion | +0.21% |
| 2016-12-31 | $4.46 Billion | -5.05% |
| 2015-12-31 | $4.70 Billion | +10571.11% |
| 2014-12-31 | $44.02 Million | -41.64% |
| 2013-12-31 | $75.42 Million | +227.45% |
| 2012-12-31 | $23.03 Million | +393.66% |
| 2011-12-31 | $4.67 Million | +47.33% |
| 2010-12-31 | $3.17 Million | +463.52% |
| 2009-12-31 | $562.00K | -96.40% |
| 2008-12-31 | $15.61 Million | -35.10% |
| 2007-12-31 | $24.06 Million | +534.83% |
| 2006-12-31 | $3.79 Million | -77.65% |
| 2005-12-31 | $16.95 Million | +182.96% |
| 2004-12-31 | $5.99 Million | -74.49% |
| 2003-12-31 | $23.49 Million | -12.53% |
| 2002-12-31 | $26.85 Million | -12.16% |
| 2001-12-31 | $30.57 Million | -1.58% |
| 2000-12-31 | $31.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Royalty Pharma Plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 235631800000.0% over the analyzed period, indicating profitable operations and earnings retention.
Royalty Pharma Plc Net Assets Breakdown (December 2025)
Royalty Pharma Plc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $2.36 Billion | 36.38% |
| Common Stock | $106.00K | 0.00% |
| Other Components | $4.12 Billion | 63.62% |
| Total Equity | $6.48 Billion | 100.00% |
Royalty Pharma Plc Competitors by Market Cap
The table below lists competitors of Royalty Pharma Plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FANUC CORP.UNSP.ADR 1/10
F:FUCA
|
$29.28 Billion |
|
Credicorp Ltd
MX:BAPN
|
$29.37 Billion |
|
Bharat Electronics Limited
NSE:BEL_old
|
$29.41 Billion |
|
George Weston Limited
TO:WN
|
$29.41 Billion |
|
Givaudan SA
SW:GIVN
|
$29.21 Billion |
|
Huaneng Lancang River Hydropower Inc Class A
SHG:600025
|
$29.20 Billion |
|
Fresenius SE & Co. KGaA
XETRA:FRE
|
$29.19 Billion |
|
HOCHTIEF Aktiengesellschaft
F:HOT
|
$29.17 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Royalty Pharma Plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,946,581,000 to 6,476,900,000, a change of -469,681,000 (-6.8%).
- Net income of 770,947,000 contributed positively to equity growth.
- Dividend payments of 378,253,000 reduced retained earnings.
- Share repurchases of 1,227,383,000 reduced equity.
- Other factors increased equity by 365,008,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $770.95 Million | +11.9% |
| Dividends Paid | $378.25 Million | -5.84% |
| Share Repurchases | $1.23 Billion | -18.95% |
| Other Changes | $365.01 Million | +5.64% |
| Total Change | $- | -6.76% |
Book Value vs Market Value Analysis
This analysis compares Royalty Pharma Plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.70x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 751.80x to 5.70x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $0.09 | $65.93 | x |
| 2001-12-31 | $0.09 | $65.93 | x |
| 2002-12-31 | $0.08 | $65.93 | x |
| 2003-12-31 | $0.07 | $65.93 | x |
| 2004-12-31 | $0.02 | $65.93 | x |
| 2005-12-31 | $0.05 | $65.93 | x |
| 2006-12-31 | $0.01 | $65.93 | x |
| 2007-12-31 | $0.07 | $65.93 | x |
| 2008-12-31 | $0.04 | $65.93 | x |
| 2009-12-31 | $0.00 | $65.93 | x |
| 2010-12-31 | $0.01 | $65.93 | x |
| 2011-12-31 | $0.01 | $65.93 | x |
| 2012-12-31 | $0.07 | $65.93 | x |
| 2013-12-31 | $0.21 | $65.93 | x |
| 2014-12-31 | $0.12 | $65.93 | x |
| 2015-12-31 | $7.70 | $65.93 | x |
| 2016-12-31 | $7.32 | $65.93 | x |
| 2017-12-31 | $12.59 | $65.93 | x |
| 2018-12-31 | $12.67 | $65.93 | x |
| 2019-12-31 | $17.24 | $65.93 | x |
| 2020-12-31 | $39.88 | $65.93 | x |
| 2021-12-31 | $24.71 | $65.93 | x |
| 2022-12-31 | $9.96 | $65.93 | x |
| 2023-12-31 | $10.83 | $65.93 | x |
| 2024-12-31 | $11.69 | $65.93 | x |
| 2025-12-31 | $11.57 | $65.93 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Royalty Pharma Plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.90%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 32.42%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 3.03x
- Recent ROE (11.90%) is above the historical average (8.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -73.91% | 0.00% | 0.00x | 1.07x | $-36.94 Million |
| 2015 | 12.43% | 35.19% | 0.15x | 2.31x | $113.74 Million |
| 2016 | 12.73% | 30.14% | 0.18x | 2.36x | $121.34 Million |
| 2017 | 27.13% | 75.72% | 0.14x | 2.55x | $763.97 Million |
| 2018 | 30.70% | 76.76% | 0.16x | 2.53x | $928.91 Million |
| 2019 | 38.47% | 129.45% | 0.15x | 2.04x | $1.74 Billion |
| 2020 | 6.51% | 45.94% | 0.10x | 1.41x | $-522.26 Million |
| 2021 | 6.05% | 27.07% | 0.13x | 1.71x | $-405.13 Million |
| 2022 | 0.76% | 1.91% | 0.13x | 2.99x | $-519.98 Million |
| 2023 | 17.39% | 48.20% | 0.14x | 2.51x | $482.18 Million |
| 2024 | 12.37% | 37.95% | 0.12x | 2.62x | $164.32 Million |
| 2025 | 11.90% | 32.42% | 0.12x | 3.03x | $123.26 Million |
Industry Comparison
This section compares Royalty Pharma Plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $54,100,948
- Average return on equity (ROE) among peers: -38.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Royalty Pharma Plc (RPRX) | $9.94 Billion | -73.91% | 0.99x | $29.23 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $31.35 Million |
| Abcellera Biologics Inc (ABCL) | $11.61 Million | 2.66% | 0.85x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $99.10 Million | -22.07% | 0.12x | $260.76 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $106.02 Million | -68.71% | 0.36x | $847.89 Million |
| ABVC Biopharma Inc (ABVC) | $35.27K | -72.00% | 1.50x | $27.72 Million |
| Abivax SA American Depositary Shares (ABVX) | $48.18 Million | -23.29% | 0.12x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.58 Billion |
About Royalty Pharma Plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabe… Read more